Ipca Laboratories (NSEI:IPCALAB) - Aandelenkoers, Nieuws & Analyse

IPCALAB Overzicht aandelen

IPCALAB fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	4/6
Prestaties in het verleden	4/6
Financiële gezondheid	5/6
Dividenden	3/6

Beloningen

De winst zal naar verwachting met 29.96% per jaar groeien

De winst groeide het afgelopen jaar met 34.3%

Risicoanalyse

Geen risico's gedetecteerd voor IPCALAB uit onze risicocontroles.

Ipca Laboratories Limited Concurrenten

Ajanta Pharma

NSEI:AJANTPHARM

₹369.7b

Gland Pharma

NSEI:GLAND

₹289.1b

GlaxoSmithKline Pharmaceuticals

BSE:500660

₹409.1b

J. B. Chemicals & Pharmaceuticals

BSE:506943

₹269.3b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Ipca Laboratories
Historische aandelenkoersen
Huidige aandelenkoers	₹1,591.35
52 Week Hoogtepunt	₹1,708.65
52 Week Laag	₹1,041.00
Bèta	0.23
11 maand verandering	1.63%
3 maanden verandering	14.75%
1 Jaar Verandering	45.75%
33 jaar verandering	57.86%
5 jaar verandering	178.55%
Verandering sinds IPO	4,087.76%

Recent nieuws en updates

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Nov 17

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Sep 10

Recent updates

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Nov 17

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Sep 10

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Sep 20

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Aug 09

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Jun 08

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Mar 26

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Mar 13

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Feb 28

Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Feb 23

Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Feb 11

Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Jan 30

The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It

Jan 15

Rendement voor aandeelhouders

	IPCALAB	IN Pharmaceuticals	IN Markt
7D	3.6%	0.5%	0.5%
1Y	45.8%	42.5%	27.5%

Rendement versus industrie: IPCALAB overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 42.5 % opleverde.

Rendement versus markt: IPCALAB overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 27.5 %.

Prijsvolatiliteit

Is IPCALAB's price volatile compared to industry and market?
IPCALAB volatility
IPCALAB Average Weekly Movement	3.6%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	6.1%
10% most volatile stocks in IN Market	9.1%
10% least volatile stocks in IN Market	4.0%

Stabiele aandelenkoers: IPCALAB heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van IPCALAB is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1949	17,335	Pranay Godha	www.ipca.com

Ipca Laboratories Limited, een farmaceutisch bedrijf, produceert en verkoopt formuleringen en actieve farmaceutische ingrediënten (API's) voor verschillende therapeutische segmenten in India, Europa, Afrika, Noord- en Zuid-Amerika, Azië, het GOS en Australazië. Het bedrijf biedt API's voor de therapeutische gebieden bloeddrukverlagend, antimalaria, diuretica, DMARD en ontwormingsmiddelen. Het bedrijf levert ook generieke en merkformuleringen in de therapeutische segmenten, waaronder allergie, anti-neoplastische/kankergeneesmiddelen, anti-artritis, anti-epileptica, anti-hypertensiva, cardiologie, diabetes, dermatologie, diabetologie, verzachtende/beschermende middelen, koorts, gastro-enterologie, hematologie, helminthica, hepatoprotectiva, immunosuppressiva, infectieziekten, malaria, neurologie, neuropathische pijn en NSAID's, evenals nutraceuticals, oogheelkunde, orale antidiabetica, orthopedica, probiotica, psychiatrie, luchtwegen, reumatologie en urologie.

Ipca Laboratories Limited Samenvatting

Hoe verhouden de winst en inkomsten van Ipca Laboratories zich tot de beurswaarde?
IPCALAB fundamentele statistieken
Marktkapitalisatie	₹403.73b
Inkomsten(TTM)	₹6.61b
Inkomsten(TTM)	₹85.34b

61.1x

Koers/Winstverhouding

4.7x

P/S-verhouding

Is IPCALAB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IPCALAB resultatenrekening (TTM)
Inkomsten	₹85.34b
Kosten van inkomsten	₹30.57b
Brutowinst	₹54.78b
Overige uitgaven	₹48.16b
Inkomsten	₹6.61b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	26.06
Brutomarge	64.18%
Nettowinstmarge	7.75%
Schuld/Eigen Vermogen Verhouding	14.2%

Hoe presteerde IPCALAB op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.3%

Huidig dividendrendement

15%

Uitbetalingsratio

Betaalt IPCALAB een betrouwbaar dividend?

Zie IPCALAB dividendgeschiedenis en benchmarks

Wanneer moet je IPCALAB kopen om een aanstaand dividend te ontvangen?
Ipca Laboratories dividenddata
Ex Dividend Datum	Nov 27 2024
Betaaldatum dividend	Dec 10 2024
Dagen tot Ex-dividend	3 days
Dagen tot dividendbetaaldatum	16 days

Betaalt IPCALAB een betrouwbaar dividend?

Zie IPCALAB dividendgeschiedenis en benchmarks

IPCALAB Overzicht aandelen

Beloningen

Risicoanalyse

Ipca Laboratories Limited Concurrenten

NSEI:AJANTPHARM

₹369.7b

NSEI:GLAND

₹289.1b

BSE:500660

₹409.1b

BSE:506943

₹269.3b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Second quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Dividend of ₹2.00 announced

Ipca Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024

Ipca Laboratories Limited Announces Cessation of Manisha Premnath as Independent Director and Member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee, Effective September 21, 2024

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Recent updates

Second quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Dividend of ₹2.00 announced

Ipca Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024

Ipca Laboratories Limited Announces Cessation of Manisha Premnath as Independent Director and Member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee, Effective September 21, 2024

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Price target increased by 8.6% to ₹1,320

Ipca Laboratories Limited Approves Appointment of Vivek Shiralkar as an Independent Director

Upcoming dividend of ₹2.00 per share

Ipca Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Less than half of directors are independent

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Ipca Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Full year 2024 earnings released: EPS: ₹25.82 (vs ₹18.58 in FY 2023)

Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

Ipca Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director

Price target increased by 9.1% to ₹1,097

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Ipca Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

CFO, MD & Executive Director recently sold ₹22m worth of stock

Price target increased by 9.7% to ₹987

Upcoming dividend of ₹2.00 per share at 0.2% yield

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023

Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Ipca Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q4, 2023 Results on May 29, 2023

Price target decreased by 7.1% to ₹858

Investor sentiment deteriorates as stock falls 15%

Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Consensus EPS estimates fall by 21%

Third quarter 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million.

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on December 7, 2022

Ipca Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Insider recently sold ₹1.7m worth of stock

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Ipca Laboratories Limited Approves Interim Dividend as Final Dividend for Financial Year Ended 31St March, 2022

Now 20% undervalued

Ipca Laboratories Limited Announced Demise of Dev Parkash Yadava, Non-Executive and Independent Director

Ipca Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Now 20% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations